Iván R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on X:
“EMERALD Study Results: Trastuzumab-Pertuzumab (HP) plus chemotherapy in advanced/metastatic HER2+ breast cancer
Findings:
PFS:
-Eribulin + HP: 14.0 months.
-Taxanes + HP: 12.9 months (HR: 0.95, 95% CI: 0.76–1.19).
-Confirms non-inferiority of eribulin compared to taxanes.
OS:
-Eribulin: Not reached.
-Taxanes: 65.3 months.
Quality of Life: -Longer time to deterioration with eribulin.
Adverse Events:
-Taxanes: More infusion reactions, diarrhea, skin effects, and edema.
-Eribulin: More neutropenia.
Eribulin + HP is a safe and effective first-line treatment option for patients with advanced or metastatic HER2+ breast cancer. ”
